Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan;11(1):32-6.
doi: 10.2450/2012.0151-12. Epub 2012 Sep 12.

Liver disease, coagulopathies and transfusion therapy

Pier Mannuccio Mannucci  1 , Armando Tripodi
Affiliations
Review

Liver disease, coagulopathies and transfusion therapy

Pier Mannuccio Mannucci et al. Blood Transfus. 2013 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the steps of coagulation factor activation (indicated by solid arrows) leading to thrombin formation and the corresponding steps of inhibition (indicated by broken arrows). Coagulation factors are represented by roman numbers. TF, tissue factor. AT, antithrombin. TM-APC-PS, thrombomodulin-activated protein C-protein S. TFPI, tissue factor pathway inhibitor.
Figure 2
Figure 2
Schematic representation of fibrinolysis steps leading to plasmin formation. Solid and broken arrows represent activators and anti-activators. HRGP, histidin-rich glycoprotein. TAFI, thrombin activatable fibrinolysis inhibitor. PAI, tissue plasminogen activator inhibitor. PI, plasmin inhibitor. FXIIa, activated factor XII. tPA, tissue-type plasminogen activator. uPA, urokinase-type plasminogen activator.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mammen EF. Coagulation defects in liver disease. Med Clin North Am. 1994;78:545–54. - PubMed
    1. Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. 1976;2:542–45. - PMC - PubMed
    1. Pradella P, Bonetto S, Turchetto S, et al. Platelet production and destruction in liver cirrhosis. J Hepatol. 2011;54:894–900. - PubMed
    1. Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis. 2009;13:21–31. - PubMed
    1. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116:878–85. - PubMed

MeSH terms